Cem Kuscu, PhD

Dr. Kuscu began his work in the field of genomic/epigenomics by studying the regulation of genes by using CRISPR technology. He achieved the first Cas9-ChIP-seq experiment to demostrate the effects of Cas9 in the human genome. He continues to use the CRISPR technology in them Transplant Research Institute.

Recently, he developed CRISPR-STOP method through base editing for a safer gene knock out). He has completed the tune adjustment of gene expression by using epigenetic modifications and a second project on the identification of the novel combinatorial drug regime for the treatment of one of the lowest prognostic cancer type, pancreatic cancer.

His interest at the TRI is focused on graft failure in the solid organ transplantation at the genomic and epigenomic level. The focus of this work is transplantomics. He will use his expertise in the field genome editing, cancer biology and molecular biology to understand the genetic and epigenetic effects of chronic kidney failure in the transplanted patients.